Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Masahiro Endo"'
Autor:
Masahiro Endo, Yoshihisa Enjoji, Katuo Kanmatuse, Masanori Nishinaga, Daisuke Yamazaki, Yumi Shimura
Publikováno v:
Journal of Cardiology. 75:394-399
Background Coronary computed tomography angiography (CCTA) is recommended for first-line evaluation of stable coronary artery disease, and there is a standard protocol to control heart rate (HR) in guidelines. However, time is required to decrease HR
Autor:
Takuma Oishi, Takashi Sugino, Yoko Nakasu, Kazuaki Nakashima, Kensei Shirata, Masahiro Endo, Nakamasa Hayashi, Shoichi Deguchi, Koichi Mitsuya, Koji Muramatsu
Publikováno v:
Journal of Clinical Neuroscience. 69:43-50
We aimed to estimate the frequency of intratumoral susceptibility signals (ITSS) in susceptibility-weighted imaging (SWI) in consecutive patients with primary central nervous system lymphoma (PCNSL), and to determine if pretreatment heterogeneity of
Autor:
Shota Omori, Haruki Kobayashi, Eriko Miyawaki, Masahiro Endo, Tateaki Naito, Hirotsugu Kenmotsu, Takahisa Kawamura, Kazuhisa Nakashima, Keita Mori, Kazushige Wakuda, Akira Ono, Toshiaki Takahashi, Haruyasu Murakami, Taichi Miyawaki, Nobuaki Mamesaya
Publikováno v:
In Vivo. 33:2229-2234
Background/aim To evaluate treatment efficacy of cisplatin, etoposide, and irinotecan combined therapy (PEI), platinum-rechallenge chemotherapy (Pt-Re) and amrubicin monotherapy (AMR) for patients with sensitive relapsed small cell lung cancer (SCLC)
Autor:
Aya Takahashi, Michihisa Moriguchi, Kenji Iwai, Koiku Asakura, Yuya Seko, Atsushi Umemura, Masahiro Endo, Rui Sato, Yoshito Itoh, Satoshi Tsuchiya, Takeshi Aramaki, Kanji Ymaguchi
Publikováno v:
Anticancer research. 40(7)
Background/aim To examine the factors influencing the introduction of the second-line chemotherapy and discuss the selection of first-line agent for hepatocellular carcinoma (HCC). Patients and methods We retrospectively studied 154 patients with HCC
Autor:
Haruyasu Murakami, Kazushige Wakuda, Hideaki Kojima, Tateaki Naito, Mitsuhiro Isaka, Shoji Takahashi, Masahiro Endo, Toshiaki Takahashi, Kazuhisa Nakashima, Hirotsugu Kenmotsu, Shota Omori, Akira Ono, Yasuhisa Ohde
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:609-614
Despite the efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy for patients who have undergone surgical resection of non-small cell lung cancer (NSCLC), few reports have presented survival data for Asian patients treated with adju
Autor:
Michihisa Moriguchi, Masahiro Endo, Takeshi Aramaki, Yoshito Itoh, Toshihiro Tanaka, Kanji Yamaguchi, Rui Sato, Koiku Asakura, Hideyuki Nishiofuku
Publikováno v:
Liver Cancer. 6:275-286
Objective: To investigate the validity of hepatic arterial infusion chemotherapy with low-dose 5-fluorouracil and cisplatin (LFP) versus sorafenib as first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (Vp3, Vp4)
Publikováno v:
Respiratory Medicine Case Reports
An 80-year-old Japanese woman with wet cough and dyspnea was diagnosed with pneumonia at a clinic. Antibiotics did not improve her symptoms; therefore, she was referred to our hospital one month after symptom onset. Chest radiograph findings revealed
Autor:
Koichi Mitsuya, Mitsuru Takahashi, Junji Wasa, Yoko Nakasu, Nakamasa Hayashi, Hideki Murata, Hirohisa Katagiri, Masahiro Endo, Shoichi Deguchi
Publikováno v:
Investigational New Drugs
SummaryPosterior reversible encephalopathy syndrome (PRES) is a clinical entity characterized by acute neurological symptoms such as severe headache, seizures, and visual disturbance, and by typical reversible lesion on brain magnetic resonance (MR)
Autor:
Tetsuhiko Taira, Kazuhisa Nakashima, Kazushige Wakuda, Haruyasu Murakami, Kazuhisa Takahashi, Shota Omori, Akira Ono, Takuya Oyakawa, Yasushi Hisamatsu, Toshiaki Takahashi, Takehito Shukuya, Hisao Imai, Tateaki Naito, Yasuhisa Ohde, Masahiro Endo, Keita Mori, Hiroaki Akamatsu, Ryo Ko, Hirotsugu Kenmotsu
Publikováno v:
International Journal of Clinical Oncology. 20:668-673
It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutations in the epidermal growth factor recepto
Autor:
Kazushige Wakuda, Tateaki Naito, Takuya Oyakawa, Taro Okayama, Tetsuhiko Taira, Haruyasu Murakami, Akira Tanuma, Hirotsugu Kenmotsu, Hisao Imai, Takashi Aoyama, Takuya Ohashi, Katsuhiro Omae, Toshiaki Takahashi, Takeshi Ishii, Shota Omori, Hitomi Shiozaki, Nobuyuki Yamamoto, Masahiro Endo, Akira Ono, Kazuhisa Nakashima, Madoka Kimura, Keita Mori, Yoshiyuki Masuda
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
BMC Cancer
BMC Cancer
Elderly patient with advanced cancer is one of the most vulnerable populations. Skeletal muscle depletion during chemotherapy may have substantial impact on their physical function. However, there is little information about a direct relationship bet